Latest Headlines

Latest Headlines

NEJM lays out questions--and facts--about Provenge

Shares of Dendreon (NASDAQ: DNDN) soared into the stratosphere in the lead-up to Provenge's approval--and then promptly started tumbling fast as all sorts of questions arose about supply issues and

Dendreon shares routed by Medicare Provenge review news

Shares of Dendreon (DNDN) took a nasty hit on Wednesday after Medicare officials announced plans to review its new prostate cancer vaccine to see whether the federal program should pay to provide it

Dendreon scrambles to boost Provenge production

Dendreon is ramping up production of its brand-new prostate cancer vaccine Provenge-- but not nearly fast enough. The supply will fall far short of demand for at least the next 12 months. Only two

Provenge gets clean bill of health on safety, side effects

Dendreon's (NASDAQ: DNDN) megablockbuster launch of the prostate cancer vaccine Provenge got an added boost earlier in the week when researchers unveiled a new block of data that underscores the

Who's the next Dendreon?

One popular new game in biotech investment circles is guessing the cancer vaccine developer that is most likely to follow in the footsteps of Dendreon (NASDAQ: DNDN), which braved some considerable

Sarcoma Foundation calls for radical change in FDA review process

Mark Thornton, a former medical officer at the FDA and current president of the Sarcoma Foundation of America, uses the recent Provenge approval to illustrate why the FDA needs to reverse its

Hunt for the next big cancer vaccine fraught with peril

After Dendreon won a historic approval a week ago for Provenge, the world's first therapeutic cancer vaccine, a host of developers started to flag their own therapeutic vaccine programs. But in the

Personalized manufacturing will limit Provenge supply

A lack of manufacturing bandwidth is putting the squeeze on Dendreon's newly approved immunotherapy, Provenge. The prostate cancer drug's demanding manufacturing process is so far approved in only

FDA approves Provenge for prostate cancer

Amongst the daily catch of healthcare-related news releases, some announcements are just more important than others. That's certainly the case with Dendreon's announcement that the FDA has approved

Dendreon CEO cashes in $28.8M of shares on Provenge OK

Dendreon (NASDAQ: DNDN) CEO Mitchell Gold had a busy day last Thursday, when the FDA capped the developer's 15-year quest with an approval of the revolutionary new prostate cancer vaccine Provenge.